Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Proactive CEO Spotlight Investor Session, March 2017
19 slides from Cynata Therapeutics's conference presentation, Mar 10, 2017
Slide 1: ASX Announcement: Proactive Investor Conference Presentation
ASX ANNOUNCEMENT 10 March 2017 For personal use only Proactive Investor Conference Presentation Please find enclosed an Investor Presentation, which Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), will be presenting at the Proactive’s CEO Spotlight Inv
Slide 2: A Next Generation Stem Cell Company
For personal use only A Next Generation Stem Cell Company Dr. Ross Macdonald, CEO Cynata Therapeutics Limited Proactive Investor Lunch, March 2017 www.cynata.com
Slide 3: Important Information
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necess
Slide 4: Key Facts
Key Facts Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company. For personal use only ASX CODE CYP COMMENCED OPERATIONS November 2013 MARKET CAP (10 March 17) A$ 44m SHARES ON ISSUE 90m1 CASH $ 3.9m as at 31 Dec 2016 $10m raised in Jan 2017 via placement and Fujifilm
Slide 5: Why Invest in Cynata?
Why Invest in Cynata? Competitive Strengths For personal use only Disruptive platform technology, CymerusTM facilitates the manufacture of allogeneic mesenchymal stem cells at scale Partnership with FUJIFILM: global leader in regenerative medicine World-first Phase 1 clinical trial Near term value c
Slide 6: Cynata Milestones
Cynata Milestones For personal use only Collaborations Strategic Partnership Final report of with leading with FUJIFILM and initial preclinical clinical research $3.97m equity study in asthma centre Harvard Clinical trial for placement by demonstrating Research GvHD approved by Research beneficial e
Slide 7: Strong Partnerships
Strong Partnerships • Definitive option agreement to an exclusive, worldwide licence to market and sell CYP-001 for graft-versus-host disease (GvHD) For personal use only A major multinational with • Strategic acquisition of CYP shares: AUD$3.97m @ 35% premium businesses in healthcare, graphic syste
Slide 8: About Cynata's Technology
About Cynata’s Technology For personal use only (animation) www.cynata.com
Slide 9: Why Are Stem Cells Important?
Why Are Stem Cells Important? Stem cells are important because of their potential For personal use only to regenerate and repair damaged tissue Stem cells as therapies for disease have attracted significant media interest and medical research for a wide range of diseases Mesenchymal Stem Cells (MSCs
Slide 10: Mesenchymal Stem Cell (MSC) Therapeutics
Mesenchymal Stem Cell (MSC) Therapeutics ~652* open clinical studies using MSCs including: For personal use only Annual Market Value ($US) • Profound legislative changes to expedite stem cell therapies (Japan) • Massive government investment e.g. California (CIRM): US$3bn • Significant potential app
Slide 11: Cynata's Therapeutic Product Pipeline
Cynata’s Therapeutic Product Pipeline For personal use only www.cynata.com
Slide 12: Graft vs Host Disease
Graft vs Host Disease Potentially fatal complication that can occur after a For personal use only What bone marrow transplant in cancer patients when the donor’s immune cells attack the host (patient). Global GvHD market value estimated to Market increase from US$295m in 2013 to US$544m in 2023 1. C
Slide 13: Current Challenge for MSC Medicines: Manufacture
Current Challenge for MSC Medicines:: Manufacture For personal use only Recruitment and Issues with Inconsistent Reduced Significant qualification of donors is costly, production product product intra- and time consuming scale-up quality efficacy inter- donor and has variability logistical challenge
Slide 14: The Solution: Cynata's Cymerus Platform
TM The Solution: Cynata’s Cymerus Platform For personal use only An innovative and efficient production process that enables commercial-scale manufacture of a consistent, robust and premier grade MSC product: …better, cheaper, faster TM Cymerus Cells Cells are re- Induction of from one programmed iP
Slide 15: Cynata's Cymerus: Outstanding Pedigree
Cynata’s Cymerus : TM Outstanding Pedigree For personal use only Inventors include: Dr James Thomson • In 1998 derived the first human embryonic stem cell line • 2007 derived human induced pluripotent stem cells …and Prof Igor Slukvin, co-founder and author of >70 publications in the stem cell field
Slide 16: Business Model: Commercial Partnerships
BUSINESS MODEL: Commercial Partnerships Capital efficient license-driven strategy For personal use only Revenue Streams - License payments • Definitive agreement: equity, Licensing CymerusTM platform upfronts, milestones and to big pharma/biotech Already royalties secured • Strategic investor; bring
Slide 17: High Activity Pipeline
High Activity Pipeline What’s Next? For personal use only Commence WORLD-FIRST Phase 1 trial; Formal interaction with FDA Licence option agreement with apceth Additional commercial + development partnerships Continued success of MSC-based therapeutics www.cynata.com
Slide 18: Investment Highlights Summary
For personal use only Investment Highlights Summary • Only company in the world that can mass-produce therapeutic stem cells at a consistent quality and affordable cost • Cynata’s Cymerus™ technology overcomes the challenges inherent in first generation production methods and the regulatory hurdles
Slide 19: Thank you for your attention
Thank you for your attention For personal use only Cynata Therapeutics Limited Suite 1, 1233 High Street, Armadale, Victoria 3143 Contact details: ross.macdonald@cynata.com +61 (0) 412 119343 www.cynata.com www.cynata.com
Cynata Therapeutics — Proactive CEO Spotlight Investor Session, March 2017 on 6ix